Evogene Ltd. (NASDAQ:EVGN) Sees Significant Decline in Short Interest

Evogene Ltd. (NASDAQ:EVGN) saw a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 28,100 shares, a decline of 15.4% from the February 28th total of 33,200 shares. Based on an average daily volume of 35,800 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.5% of the company’s shares are short sold.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Jane Street Group LLC bought a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned 0.40% of Evogene as of its most recent SEC filing. Institutional investors own 10.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Alliance Global Partners reaffirmed a “buy” rating on shares of Evogene in a research report on Friday, March 7th. StockNews.com initiated coverage on Evogene in a research report on Wednesday, March 26th. They set a “sell” rating for the company.

Evogene Stock Down 3.5 %

Shares of NASDAQ EVGN opened at $1.26 on Tuesday. The company has a market capitalization of $6.78 million, a PE ratio of -0.28 and a beta of 1.28. Evogene has a twelve month low of $1.20 and a twelve month high of $9.00. The firm has a fifty day simple moving average of $1.47 and a 200 day simple moving average of $1.83.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.78. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The firm had revenue of $1.61 million during the quarter, compared to analyst estimates of $3.63 million. During the same period last year, the company posted ($1.30) EPS.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.